Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive, heterogeneous cancer with limited treatment options.
• Current chemotherapy for TNBC faces challenges due to toxicity and acquired resistance, necessitating novel therapeutic strategies.
• Receptor tyrosine kinases (RTKs) play crucial roles in cell signaling and are often dysregulated in TNBC, correlating with tumor progression and poor patient outcomes.

Purpose of the Study:

• To review the antitumor activity of RTK inhibitors in preclinical TNBC models.
• To provide insights into ongoing clinical trials evaluating RTK inhibitors for TNBC treatment.

Main Methods:

• Literature review of preclinical studies on RTK inhibitors in TNBC.
• Analysis of clinical trial data for RTK inhibitors in TNBC patients.

Main Results:

• RTK overexpression and deregulation are common in TNBC, linked to adverse prognostic factors.
• Preclinical data suggest significant antitumor effects of various RTK inhibitors against TNBC models.
• Clinical trials are investigating the efficacy and safety of RTK inhibitors in TNBC patients.

Conclusions:

• Targeting RTKs represents a rational and potentially effective therapeutic strategy for TNBC.
• Further research and clinical evaluation of RTK inhibitors are warranted to improve TNBC patient outcomes.